Cronin K J, Williams N N, Kerin M J, Creagh T A, Dervan P A, Smith J M, Fitzpatrick J M
Department of Urology, Mater Misericordiae Hospital, Dublin, Ireland.
J Urol. 1994 Sep;152(3):834-6. doi: 10.1016/s0022-5347(17)32585-5.
Renal cell carcinoma is a tumor, the prognosis and behavior of which remain poorly understood. Proliferating cell nuclear antigen levels have been shown to act as an independent prognostic variable in a variety of malignancies. Proliferating cell nuclear antigen was evaluated in 59 cases of renal cell carcinoma, and the results were correlated with existing clinicopathological variables and survival. Proliferating cell nuclear antigen index (percentage of tumor cells positive for proliferating cell nuclear antigen) did not correlate with stage, grade or ploidy. To assess survival, tumors with proliferating cell nuclear antigen indexes of greater than and less than 60% were compared. The 24 patients with a high index (greater than 60%) had a significantly worse survival than did 35 with a low index (less than 60%, p < 0.001). Therefore, the prognostic potential of proliferating cell nuclear antigen in renal cell carcinoma is promising and may be of clinical value in the management of patients with renal cell carcinoma.
肾细胞癌是一种肿瘤，其预后和行为仍知之甚少。增殖细胞核抗原水平已被证明在多种恶性肿瘤中可作为独立的预后变量。对59例肾细胞癌患者的增殖细胞核抗原进行了评估，并将结果与现有的临床病理变量及生存率进行了关联分析。增殖细胞核抗原指数（增殖细胞核抗原阳性的肿瘤细胞百分比）与分期、分级或倍性无关。为评估生存率，对增殖细胞核抗原指数大于和小于60%的肿瘤进行了比较。24例高指数（大于60%）患者的生存率明显低于35例低指数（小于60%）患者（p<0.001）。因此，增殖细胞核抗原在肾细胞癌中的预后潜力很有前景，可能对肾细胞癌患者的管理具有临床价值。
